Currently, the diagnosis of atrophic gastritis and gastric cancer are mainly made by endoscopy and histopathology. Our study aimed to explore the practical value of Serum Pepsinogen I/II and gastrin-17 in gastric cancer diagnosis and prognosis. We collected 60 cases of gastric ulcer from February 2015 to November 2016 as gastric ulcer group, and 40 cases of gastric cancer treated in the same period as gastric cancer group. In 3 years after gastric cancer, 20 patients were served as postoperative gastric cancer group, and 70 healthy subjects as control group. The results showed that serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes were tested by enzyme-linked immunosorbent assay (ELISA). The serum PGI level of gastric ulcer group was higher than control group (P < 0.05). The serum G-17 concentrations in gastric ulcer group, gastric cancer group, and postoperative gastric cancer group were all higher than control group (P < 0.05). The area under receiver operating characteristic (ROC) curve of PGI screening was 0.905 and the best cutoff point was PGI < 75 µg/L. Their sensitivity and specificity were 87.2% and 75.1%; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII < 4. Their sensitivity and specificity were 88.9% and 62.3%. Multi logistical regression showed that the level of serum PGI, PGI, and G-17 and the odds ratio (OR) level of gastric cancer risk were 2.093, 2.653, and 0.494 (P < 0.05). The examination of Serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes can be used in the diagnosis and prognosis of gastric cancer and has a rather high practical value in monitoring recurrence in postoperative gastric cancer patients.
Introduction
Gastric cancer, one of the digestive system malignant tumors, with the characteristic of both high prevalence and high mortality, has become one of the most common diseases which damage human's health and safety. The number of patients with gastric cancer is increasing, and because the symptom of early gastric cancer is not so obvious, many patients are diagnosed with elderly gastric cancer. 1 With the significant progress of medical treatment in recent years, many clinical observations showed that early diagnosis and treatment can effectively rise patients' 5 year survival rate and improve their prognosis. Therefore, exploring the monitoring indexes of gastric cancer is beneficial to the early diagnosis and treatment of patients with gastric cancer. 2, 3 Now we mainly use pathological examination under gastroscope to diagnose gastric cancer, but as it is an invasive operation and some patients are impossible to tolerate the operation, so it has certain limits in early gastric cancer diagnosis. 4, 5 To further explore the practical value of Serum Pepsinogen I/II, gastrin-17 in diagnosis and prognosis of gastric cancer, we examined and analyzed the indexes mentioned above in patients with gastric ulcer, patients with gastric cancer, postoperative patients, and healthy people to provide theoretical reference for early diagnosis and prognosis of gastric cancer.
Data and methods

General data
Our study was approved by the ethics committee of our hospital. All patients provided written informed consent. Sixty cases of patients with gastric ulcer treated in our hospital from February 2015 to November 2016 were enrolled in this research as gastric ulcer group, 39 cases of them were males, and 21 cases of them were females; their age was from 43 to 75 with a mean age of 65.7 ± 3.1 years. Forty cases of patients with gastric cancer treated in our hospital in the same period were enrolled in the research as gastric cancer group, 25 cases of them were males, and 15 cases of them were females; their age was from 44 to 72 with a mean age of 65.6 ± 2.4 years. Among them, 30 cases in clinical stage II and 10 cases in clinical stage III. Twenty cases of 3 years postoperative gastric cancer patients treated in our hospital were enrolled in this research as postoperative gastric cancer group, 15 cases of them were males, and 5 cases of them were female; their age were from 44 to 72 with a mean age of 65.8 ± 3.1 years. The patients with postoperative gastric cancer were followed by telephone and none of their cancer reappeared until now. Seventy cases of healthy people examined in our hospital were recruited in the research as control group. Forty cases of them were males and 30 cases of them were females; their age was form 41 to 75 with a mean age of 65.1 ± 2.1 years. All cases were confirmed by gastroscope or pathology slice after operation.
Main reagents and equipments
PGI, PGII, G-17 kit (by Wuhan Easy Diagnosis Biomedicine Co., Ltd), Microplate Reader (made by Shanghai Woyuan Technology Co., Ltd).
Measuring method
Blood was gained from all the patients though vein with fasting abdomen. Serum was isolated from the blood within 2 h and frozen, spare parts in -20°C. Use enzyme-linked immunosorbent assay (ELISA) to examine serum PGI, PGII, G-17, operation should be carry out according to kit instructions.
Statistical analysis
All results were analyzed by SPSS 21.0. Mean ± standard deviation was analyzed using analysis of variance in completely random design. Multiple comparisons between groups were compared with least significant difference (LSD) analysis of variance. P < 0.05 means a significant difference. Comparison of quantitative data between two groups was analyzed by t-test in a completely random design. Use receiver operating characteristic (ROC) curve to calculate the best cutoff point of all indexes in gastric cancer examination. The connection between serum PGI, PGII, and G-17 level and gastric cancer was analyzed by logistic regression analysis.
Results
Comparisons on PGI, PGII, and G-17 level in different groups
The serum PGI level of gastric ulcer group was higher than control group (P < 0.05), but there is no statistical significance on PGII level between gastric ulcer group and control group (P < 0.05); the serum PGI and PGII levels of patients in gastric cancer group were lower than those in control group (P < 0.05). Compared with gastric cancer group, serum PGI and PGII concentrations of postoperative gastric cancer group were increased (P < 0.05). The serum G-17 concentration in gastric ulcer group, gastric cancer group, and postoperative gastric cancer group were all higher than control group (P < 0.05) (see Table 1 ).
Use of PGI, PGI/PGII, and G-17 level to diagnose best cut-off value, the sensitivity, and specificity of gastric cancer
Gastric cancer group was chosen to draw the ROC curve of PGI and PGI/PGII. The area under ROC curve of PGI screening was 0.905 and the best cutoff point was PGI < 75 µg/L. Their sensitivity and specificity were 87.2% and 75.1%, respectively; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII < 4. Their sensitivity and specificity were 88.9% and 62.3%, respectively (Figure 1 ).
Logistical regression analysis on the connection between serum PGI, PGII, G-17 level, and gastric cancer
Multi logistical regression was performed to analyze patients' age, sex, the size of tumor, clinical stage, lymphatic metastasis, and the level of serum PGI, PGII, and G-17, showing that the level of serum PGI, PGII, and G-17 and the odds ratio (OR) level of gastric cancer risk were 2.093, 2.653, and 0.494 (P < 0.05) (see Table 2 ).
Discussion
Serum PG is a precursor without activity which belongs to digestive enzymes, and it mainly produced by the chief cells in gastric mucosa and the neck mucosa cells. Studies have shown that serum PG is closely connected with the appearance and development of gastric cancer. 6 Our research showed that the serum PGI level of gastric ulcer group was higher than control group (P < 0.05); the levels of serum PGI and PGII in gastric cancer group were both lower than that in control group (P < 0.05); compared with gastric cancer group, serum PGI and PGII levels in postoperative gastric cancer group were both increased (P < 0.05), which means that the examination of serum PG was beneficial for diagnosis of gastric cancer in early stage.
Previous studies showed that gastrin can be produced in normal gastric epithelial and other tissues and the change of gastrin level may be a precursor to gastric cancer. 7, 8 The examination of serum PG and G-17, as a noninvasive, simple in operation, and small pain method, can be used in the clinical diagnosis of digestive diseases. Studies have shown that the change of serum PG is a subclinical index of precursor to gastric cancer. [9] [10] [11] There are some certain connections between serum PG level and gastric carcinoma: the lower PGI/PGII is, the higher the rate of gastric cancer is.
This study showed that the area under ROC curve of PGI screening was 0.905 and the best cutoff point was PGI < 75 µg/L. Their sensitivity and specificity were 87.2% and 75.1%; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII < 4. Their sensitivity and specificity were 88.9% and 62.3%. It is also worth mentioning that as the area under ROC curve of gastric cancer examination was relatively small, so we did not get the best cutoff point of G-17 in gastric cancer, which may be related to small sample and unstable serum gastrin which may be affected by eating and pathophysiological changing and other factors. Multi logistical regression results showed that in the appearance and development of gastric cancer, many biomarkers may be produced and the sensitivity and specificity of PGI, PGII, and G-17 in the diagnosis of gastric cancer were different. Single detection in diagnosis had certain limits while combined detection of cancer makers may complement one another.
In conclusion, the examination of Serum Pepsinogen I/II and gastrin-17 had a high practical value in the diagnosis and prognosis of gastric cancer and had clinical value in monitoring recurrence in postoperative gastric cancer patients. Our study may provide a new insight in early gastric cancer diagnosis.
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